UTHR – United Therapeutics Corporation
United Therapeutics CorporationUTHR
$294.28Name : United Therapeutics Corporation
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $13,309,195,264.00
EPSttm : 25.64
United Therapeutics Corporation
$294.28
7.13%$19.58Float Short %
3.64
Margin Of Safety %
18
Put/Call OI Ratio
2.1
EPS Next Q Diff
0.21
EPS Last/This Y
0.6
EPS This/Next Y
0.71
Price
294.28
Target Price
381.91
Analyst Recom
1.67
Performance Q
0.15
Relative Volume
4.45
Beta
0.57
Ticker: UTHR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | UTHR | 294.49 | 0.69 | 0.17 | 8578 |
| 2025-07-07 | UTHR | 291 | 0.70 | 2.77 | 8566 |
| 2025-07-08 | UTHR | 294.42 | 0.82 | 1.68 | 9216 |
| 2025-07-09 | UTHR | 300.57 | 0.92 | 11.96 | 10083 |
| 2025-07-10 | UTHR | 300.07 | 1.10 | 2.51 | 11172 |
| 2025-07-11 | UTHR | 295.5 | 1.41 | 26.41 | 13086 |
| 2025-07-14 | UTHR | 297.7 | 1.58 | 0.11 | 14077 |
| 2025-07-15 | UTHR | 293.42 | 1.52 | 0.06 | 14380 |
| 2025-07-16 | UTHR | 298.15 | 1.42 | 0.57 | 14853 |
| 2025-07-17 | UTHR | 297.48 | 1.42 | 20.06 | 14960 |
| 2025-07-18 | UTHR | 291.78 | 1.52 | 2.94 | 15605 |
| 2025-07-21 | UTHR | 293.4 | 1.63 | 8.11 | 14876 |
| 2025-07-22 | UTHR | 297.63 | 1.71 | 0.30 | 15461 |
| 2025-07-23 | UTHR | 305.65 | 1.70 | 1.94 | 15504 |
| 2025-07-24 | UTHR | 306.54 | 1.69 | 0.02 | 16921 |
| 2025-07-25 | UTHR | 304.73 | 1.54 | 0.81 | 17550 |
| 2025-07-28 | UTHR | 298.09 | 1.54 | 1.05 | 17797 |
| 2025-07-29 | UTHR | 297.16 | 1.58 | 0.44 | 18613 |
| 2025-07-30 | UTHR | 281.81 | 1.55 | 15.64 | 18882 |
| 2025-07-31 | UTHR | 274.72 | 2.14 | 1.78 | 22789 |
| 2025-08-01 | UTHR | 294.19 | 2.10 | 3.82 | 23385 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | UTHR | 294.49 | 26.2 | 88.8 | 27.66 |
| 2025-07-07 | UTHR | 290.01 | 26.2 | 60.5 | 27.66 |
| 2025-07-08 | UTHR | 294.42 | 26.2 | 125.1 | 27.66 |
| 2025-07-09 | UTHR | 300.56 | 26.2 | 140.4 | 27.66 |
| 2025-07-10 | UTHR | 300.16 | 26.2 | 91.4 | 27.66 |
| 2025-07-11 | UTHR | 295.52 | 26.2 | 57.4 | 27.66 |
| 2025-07-14 | UTHR | 297.68 | 26.2 | 110.3 | 27.66 |
| 2025-07-15 | UTHR | 293.24 | 26.2 | 61.3 | 27.66 |
| 2025-07-16 | UTHR | 298.18 | 26.2 | 131.7 | 27.66 |
| 2025-07-17 | UTHR | 297.33 | 26.2 | 88.0 | 27.66 |
| 2025-07-18 | UTHR | 292.01 | 26.2 | 54.7 | 27.66 |
| 2025-07-21 | UTHR | 293.22 | 26.2 | 103.4 | 27.66 |
| 2025-07-22 | UTHR | 297.75 | 26.2 | 129.2 | 27.66 |
| 2025-07-23 | UTHR | 305.61 | 26.2 | 151.4 | 27.66 |
| 2025-07-24 | UTHR | 306.41 | 24.8 | 100.0 | 27.26 |
| 2025-07-25 | UTHR | 304.50 | 24.8 | 80.7 | 27.26 |
| 2025-07-28 | UTHR | 298.42 | 24.8 | 50.4 | 27.26 |
| 2025-07-29 | UTHR | 297.56 | 24.8 | 90.0 | 27.26 |
| 2025-07-30 | UTHR | 281.95 | 24.8 | -21.6 | 27.26 |
| 2025-07-31 | UTHR | 274.70 | 24.8 | 36.4 | 27.26 |
| 2025-08-01 | UTHR | 294.28 | 9.7 | 206.6 | 27.04 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | UTHR | -17.31 | 1.41 | 3.67 |
| 2025-07-07 | UTHR | -17.31 | 1.42 | 3.67 |
| 2025-07-08 | UTHR | -16.70 | 1.42 | 3.67 |
| 2025-07-09 | UTHR | -16.70 | 1.42 | 3.67 |
| 2025-07-10 | UTHR | -16.70 | 1.42 | 3.67 |
| 2025-07-11 | UTHR | -16.76 | 1.42 | 3.56 |
| 2025-07-14 | UTHR | -17.12 | 1.66 | 3.56 |
| 2025-07-15 | UTHR | -16.52 | 1.66 | 3.56 |
| 2025-07-16 | UTHR | -16.52 | 1.66 | 3.56 |
| 2025-07-17 | UTHR | -16.52 | 1.66 | 3.56 |
| 2025-07-18 | UTHR | -16.52 | 1.66 | 3.56 |
| 2025-07-21 | UTHR | -16.52 | 1.41 | 3.56 |
| 2025-07-22 | UTHR | -16.52 | 1.41 | 3.56 |
| 2025-07-23 | UTHR | -15.90 | 1.41 | 3.56 |
| 2025-07-24 | UTHR | -15.90 | 1.41 | 3.56 |
| 2025-07-25 | UTHR | -15.90 | 1.41 | 3.64 |
| 2025-07-28 | UTHR | -16.58 | -0.26 | 3.64 |
| 2025-07-29 | UTHR | -15.96 | -0.26 | 3.64 |
| 2025-07-30 | UTHR | -15.96 | -0.26 | 3.64 |
| 2025-07-31 | UTHR | -15.91 | -0.26 | 3.64 |
| 2025-08-01 | UTHR | -15.91 | -0.26 | 3.64 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
6.41
Avg. EPS Est. Current Quarter
6.9
Avg. EPS Est. Next Quarter
6.62
Insider Transactions
-15.91
Institutional Transactions
-0.26
Beta
0.57
Average Sales Estimate Current Quarter
821
Average Sales Estimate Next Quarter
807
Fair Value
348.57
Quality Score
100
Growth Score
98
Sentiment Score
6
Actual DrawDown %
29.6
Max Drawdown 5-Year %
-33
Target Price
381.91
P/E
11.49
Forward P/E
10.19
PEG
2.57
P/S
4.32
P/B
1.85
P/Free Cash Flow
12.46
EPS
25.61
Average EPS Est. Cur. Y
27.04
EPS Next Y. (Est.)
27.76
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
40.36
Relative Volume
4.45
Return on Equity vs Sector %
-6.4
Return on Equity vs Industry %
9.5
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.62
EBIT Estimation
206.6
United Therapeutics CorporationSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1305
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading